Supplemental Table S1. Categorization of patients by *FLT3-ITD* and *TKD* mutations

|  |  |  |
| --- | --- | --- |
|  | **Venetoclax + Azacitidine**  **(n)** | **Azacitidine**  **(n)** |
| FLT3-ITD only and NPM1 co-mutated | 10 | 5 |
| FLT3-ITD only  and NPM1 wild type | 19 | 8 |
| *FLT3-ITD* < 0.5 (with or without TKD) and *NPM1* co-mutated | 8 | 4 |
| *FLT3-ITD ≥ 0.5* (with or without TKD) and *NPM1* co-mutated | 2 | 1 |
| *FLT3-ITD* < 0.5 (with or without TKD) and *NPM1* wild type | 13 | 4 |
| *FLT3-ITD* *≥* 0.5 (with or without TKD) and *NPM1* wild type | 6 | 4 |
| FLT3-TKD only and NPM1 co-mutated | 6 | 4 |
| FLT3-TKD only  and NPM1 wild type | 7 | 6 |
| Note: The efficacy results of the small molecular subsets may not be generalizable to all patients; hence comparisons between treatment groups were not performed | | |